Zacks: Brokerages Expect United Therapeutics Co. (UTHR) to Post $3.58 Earnings Per Share

Wall Street analysts predict that United Therapeutics Co. (NASDAQ:UTHR) will report $3.58 earnings per share for the current quarter, Zacks reports. Six analysts have provided estimates for United Therapeutics’ earnings, with the highest EPS estimate coming in at $3.93 and the lowest estimate coming in at $3.19. United Therapeutics reported earnings per share of $4.52 in the same quarter last year, which would suggest a negative year over year growth rate of 20.8%. The firm is scheduled to announce its next quarterly earnings results on Thursday, July 27th.

On average, analysts expect that United Therapeutics will report full year earnings of $14.00 per share for the current year, with EPS estimates ranging from $10.48 to $15.42. For the next financial year, analysts forecast that the business will report earnings of $11.75 per share, with EPS estimates ranging from $9.82 to $13.40. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.12 by $0.77. The business earned $370.50 million during the quarter, compared to analyst estimates of $399.59 million. United Therapeutics had a net margin of 44.40% and a return on equity of 41.78%. The company’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.02 earnings per share.

Several equities research analysts recently weighed in on UTHR shares. Wedbush restated an “outperform” rating and set a $229.00 target price on shares of United Therapeutics in a research note on Thursday, January 5th. Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $161.00 target price for the company in a research note on Friday, January 6th. Standpoint Research cut United Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 19th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 14th. Finally, Leerink Swann boosted their target price on United Therapeutics from $127.00 to $148.00 and gave the stock a “market perform” rating in a research note on Thursday, February 23rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $135.17.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect United Therapeutics Co. (UTHR) to Post $3.58 Earnings Per Share” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/05/20/zacks-brokerages-expect-united-therapeutics-co-uthr-to-post-3-58-earnings-per-share-updated-updated.html.

In other news, Director Tommy G. Thompson sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 22nd. The stock was sold at an average price of $139.37, for a total value of $278,740.00. Following the transaction, the director now owns 2,000 shares of the company’s stock, valued at $278,740. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,173 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $167.92, for a total value of $196,970.16. Following the completion of the transaction, the chief executive officer now directly owns 1,313 shares in the company, valued at approximately $220,478.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,494 shares of company stock valued at $2,125,240. 7.50% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Bridgewater Wealth & Financial Management LLC raised its position in United Therapeutics by 6.4% in the third quarter. Bridgewater Wealth & Financial Management LLC now owns 48,028 shares of the biotechnology company’s stock worth $5,671,000 after buying an additional 2,896 shares during the last quarter. First Trust Advisors LP raised its position in United Therapeutics by 92.8% in the third quarter. First Trust Advisors LP now owns 480,971 shares of the biotechnology company’s stock worth $56,793,000 after buying an additional 231,502 shares during the last quarter. Selway Asset Management raised its position in United Therapeutics by 399.3% in the third quarter. Selway Asset Management now owns 18,475 shares of the biotechnology company’s stock worth $2,182,000 after buying an additional 14,775 shares during the last quarter. APG Asset Management N.V. raised its position in United Therapeutics by 73.7% in the third quarter. APG Asset Management N.V. now owns 416,892 shares of the biotechnology company’s stock worth $49,227,000 after buying an additional 176,900 shares during the last quarter. Finally, Virginia Retirement Systems ET AL raised its position in United Therapeutics by 5.6% in the third quarter. Virginia Retirement Systems ET AL now owns 120,000 shares of the biotechnology company’s stock worth $14,170,000 after buying an additional 6,400 shares during the last quarter.

United Therapeutics (NASDAQ:UTHR) traded up 4.32% during trading on Thursday, hitting $125.70. 1,133,176 shares of the stock traded hands. The company has a market cap of $5.65 billion, a P/E ratio of 8.24 and a beta of 1.42. United Therapeutics has a 12 month low of $97.52 and a 12 month high of $169.89. The company’s 50 day moving average price is $130.94 and its 200 day moving average price is $137.89.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

5 Day Chart for NASDAQ:UTHR

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply